抑制Rac1信号可通过改善炎症反应和肠道透性来缓解DSS诱导的大肠炎
Mei-Hong Lin1,2, Can-Hua Luo1,3, Miao-Miao Ma1
1Department of Gastroenterology, The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
Gastroenterology report
|July 30, 2025
概括
与Ras相关的C3毒素基质1 (Rac1) 抑制可缓解结肠炎症状并改善肠道屏障功能. 在大肠炎的小鼠模型中,Rac1抑制抑制了炎症反应,并恢复了紧接口的完整性.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 大肠炎的特点是肠道屏障功能障碍.
- 与Ras相关的C3毒素基质1 (Rac1) 在调节肠道屏障功能的过程中起作用.
- 在大肠炎引起的屏障破坏中,Rac1的精确分子机制需要进一步阐明.
研究的目的:
- 调查Rac1在调节大肠炎期间肠道屏障功能中的作用.
- 探索Rac1通过哪些分子机制影响大肠炎中紧密的结节.
- 在大肠炎模型中评估Rac1抑制的治疗潜力.
主要方法:
- 建立了一个硫酸 (DSS) 诱导的大肠炎小鼠模型.
- 评估了疾病活动指数 (DAI),上皮膜透性和组织学严重程度.
- 通过RT-PCR和西方布洛特分析了Rac1,NOX1和奥克卢丁的基因和蛋白质表达.
主要成果:
- DSS诱导的大肠炎小鼠表现出增加的DAI,组织学分数和上皮质透性受损.
- 服用Rac1抑制剂NSC23766显著缓解了结肠炎症状,并改善了屏障功能.
- NSC23766治疗减少了炎症标志物 (IL-6,NOX1) 并恢复了奥克卢丁蛋白水平.
结论:
- 使用NSC23766抑制Rac1可以减轻结肠炎的严重程度并增强肠道屏障的完整性.
- 保护作用很可能是通过抑制炎症反应和保持紧密结合蛋白质来调解的.
- 向Rac1代表了治疗大肠炎的潜在治疗策略.
相关概念视频
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.2K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.2K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
01:17Drugs for Treatment of Diarrhea-Predominant IBS
299
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
299
01:23Renewal of Intestinal Stem Cells
2.7K
The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.7K
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.3K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.3K